Maximum Dose of Mybetriq (Mirabegron)
The maximum dose of Mybetriq (mirabegron) extended-release tablets is 50 mg orally once daily for most adult patients with overactive bladder. 1
Standard Dosing for Adults with OAB
- Starting dose: 25 mg once daily
- Maximum dose: 50 mg once daily (can be increased after 4-8 weeks if needed) 1
- Administration: Swallow whole with water; do not chew, divide, or crush. Can be taken with or without food 1
Dose Adjustments in Special Populations
The maximum dose is reduced to 25 mg once daily in the following situations 1:
Renal Impairment
- Severe renal impairment (eGFR 15-29 mL/min/1.73 m²): Maximum 25 mg daily
- End-stage renal disease (eGFR <15 mL/min/1.73 m²) or dialysis: Not recommended
- Mild-to-moderate impairment (eGFR 30-89): Standard dosing applies (up to 50 mg)
Hepatic Impairment
- Moderate hepatic impairment (Child-Pugh Class B): Maximum 25 mg daily
- Severe hepatic impairment (Child-Pugh Class C): Not recommended
- Mild impairment (Child-Pugh Class A): Standard dosing applies (up to 50 mg)
Important Clinical Context
The 50 mg dose has been extensively validated in clinical trials and demonstrates superior efficacy compared to 25 mg, with significant reductions in incontinence episodes (approximately 1.6 per 24 hours) and micturitions (approximately 1.75 per 24 hours) versus placebo 2. A recent meta-analysis confirmed that 50 mg once daily for long-term use maximizes benefit in middle-aged and older adults with OAB 3.
Combination Therapy Considerations
When mirabegron is used in combination with antimuscarinics (particularly solifenacin 5 mg), the recommended mirabegron dose remains 50 mg daily based on the SYNERGY and BESIDE trials 4. This combination shows additive efficacy without significantly increased safety concerns, though anticholinergic side effects (dry mouth, constipation) may be slightly elevated.
Safety Monitoring
While the maximum approved dose is 50 mg, note that doses up to 100 mg were studied in clinical trials but are not FDA-approved due to dose-related increases in blood pressure and heart rate without proportional efficacy gains 2. At 50 mg, mean blood pressure increases are modest (0.5-1 mmHg greater than placebo in OAB patients) 1, but periodic blood pressure monitoring is recommended, especially in hypertensive patients.
Common pitfall: Do not exceed 25 mg in patients with severe renal impairment or moderate hepatic impairment, as drug clearance is significantly reduced in these populations 1.